Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.48 |
| ▸ | BCR | P11274 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929945 | 0.83 | CYP3A4 (0.56) | ESR2NPC1TP53MAPK1CASP3 | |
| SCHEMBL47861 | 0.82 | TSHR (0.56) | ESR2TP53MAPK1ALOX5PTGS1 | |
| SCHEMBL2097981 | 0.81 | DYRK1A (0.55) | ESR2NPC1TP53MAPK1CASP3 | |
| SCHEMBL13695139 | 0.80 | TSHR (0.45) | MAPK1MEN1KMT2A | |
| SCHEMBL1007614 | 0.79 | MCL1 (0.52) | TP53MAPK1ALOX5PTGS1 | |
| SCHEMBL29878426 | 0.78 | CYP3A4 (0.65) | ESR2NPC1TP53MAPK1CASP3 | |
| SCHEMBL22459215 | 0.77 | ESR2 (0.70) | ESR2NPC1TP53MAPK1CASP3 | |
| SCHEMBL1005170 | 0.77 | ALOX5 (0.64) | ESR2HDAC4HDAC2HDAC8MEN1 | |
| SCHEMBL12761975 | 0.77 | PKM (0.58) | ESR2NPC1TP53MAPK1CASP3 | |
| SCHEMBL12387990 | 0.76 | APP (0.70) | ALOX5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1633699-B1 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1633699-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103941-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885NPC1 4288/4885TP53 959/4885 |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, GPER1 | ESR2 2/4885NPC1 4214/4885TP53 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.